Supplemental Table 1. Summary and the assessment of the included studies.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author/ year | Study design | Region | Sample size (n) | Age range | Gender a | Prevalence of anemia (%) | RoB/quality assessment b |
| Carvalho-Costa, 2007 | Cross-sectional | North | 307 | 6 to 84 months | M/F | 51,1 | 6 |
| Vieira, 2007 | Cross-sectional | Northeast | 162 | 6 to 59 months | M/F | 55,6 | 6 |
| Arcanjo, 2007 | Randomized clinical trial | Northeast | 728 | 24 to 60 months | M/F | 37,1 | Low RoB |
| Muniz, 2007 | Cross-sectional | North | 677 | zero to 59 months | M/F | 30,6 | 6 |
| Compri, 2007 | Cross-sectional | Southeast | 357 | 4 to 24 months | M/F | 60 | 6 |
| Konstantyner, 2007 | Cross-sectional | Southeast | 212 | zero to 24 months | M/F | 51,9 | 7 |
| Modesto, 2007 | Cross-sectional | Southeast | 180 | 6 to 11 months | M/F | 30,5 | 5 |
| Souto, 2007 | Cross-sectional | Southeast | 190 | 11 to 57 months | M/F | 31,6 | 5 |
| Assunção, 2007 | Cross-sectional | South | 507 | zero to 60 months | M/F | 30,2 | 7 |
| Vitolo, 2007 | Cohort | South | 369 | 6 to 12 months | M/F | 63,7 | 6 |
| Hadler, 2008 | Randomized clinical trial | Midwest | 196 | 6 to 24 months | M/F | 56,1 | Low RoB |
| Eickmann, 2008 | Non-randomized clinical trial | Northeast | 76 | 4 to 24 months | M/F | 65,7 | Moderate RoB |
| Ferreira, 2008 | Randomized clinical trial | Northeast | 50 | 6 to 60 months | M/F | 16,1 | High RoB |
| Pinheiro, 2008 | Cross-sectional | Northeast | 104 | 6 to 59 months | M/F | 31,7 | 6 |
| Silva, 2008 | Cross-sectional | Northeast | 827 | zero to 60 months | M/F | 46,9 | 6 |
| Biscegli, 2008 | Cohort | Southeast | 52 | 32 to 78 months | M/F | 12,0 | 5 |
| Carvalho, 2008 | Cross-sectional | Southeast | 404 | 6 to 72 months | M/F | 27,0 | 6 |
| Coutinho, 2008 | Randomized clinical trial | Southeast | 108 | 6 to 24 months | M/F | 75,0 | Low RoB |
| Fujimori, 2008 | Cross-sectional | Southeast | 254 | zero to 24 months | M/F | 41,7 | 6 |
| Nogueira-de-Almeida, 2007 | Cross-sectional | Southeast | 184 | 12 to 60 months | M/F | 29,3 | 6 |
| Oliveira, 2008 | Cross-sectional | Southeast | 34 | 37 to 72 months | M/F | 8,8 | 5 |
| Prieto, 2008 | Cross-sectional | Southeast | 55 | 24 to 60 months | M/F | 23,0 | 5 |
| Rocha, 2008 | Cross-sectional | Southeast | 402 | 7 to 74 months | M/F | 28,8 | 7 |
| Shibukawa, 2008 | Cross-sectional | Southeast | 118 | 12 to 18 months | M/F | 41,5 | 6 |
| Camillo, 2008 | Cross-sectional | Southeast | 211 | 6 to 72 months | M/F | 16,1 | 6 |
| Gomes, 2008 | Cross-sectional | Southeast | 51 | zero to 60 meses | M/F | 58,8 | 6 |
| Martins, 2008 | Cross-sectional | South | 229 | 6 to 24 months | M/F | 44,6 | 6 |
| Oliveira, 2008 | Cross-sectional | South | 34 | 36 to 72 months | M/F | 8,8 | 5 |
| Jordão, 2009 | Cross-sectional | Southeast | 354 | 6 to 12 months | M/F | 66,5 | 6 |
| Bagni, 2009 | Non-randomized clinical trial | Southeast | 387 | 12 to 60 months | M/F | 41,8 | Moderate RoB |
| Costa, 2009 | Cross-sectional | Southeast | 459 | 24 to 60 meses | M/F | 20,9 | 6 |
| Konstantyner, 2009 | Cross-sectional | Southeast | 498 | 4 to 29 months | M/F | 43,6 | 7 |
| Sá, 2009 | Cross-sectional | Southeast | 399 | 6 to 36 months | M/F | 27,3 | 6 |
| Fontoura, 2009 | Cross-sectional | South | 42 | 12 to 60 months | M/F | 5,0 | 4 |
| Pazzinato, 2009 | Cross-sectional | South | 60 | 24 to 72 months | M/F | 10,0 | 4 |
| Oliveira, 2010 | Cohort | Northeast | 150 | zero to 6 months | M/F | 71,7 | 7 |
| Carvalho, 2010 | Cross-sectional | Northeast | 301 | 6 to 30 months | M/F | 92,4 | 6 |
| Oliveira, 2010 | Cross-sectional | Northeast | 628 | zero to 60 months | M/F | 46,3 | 7 |
| Oliveira, 2010 | Cross-sectional | Northeast | 502 | zero to 60 months | M/F | 37,1 | 7 |
| Teixeira, 2010 | Cross-sectional | Northeast | 330 | zero to 6 months | M/F | 65,2 | 6 |
| Vieira, 2010 | Cross-sectional | Northeast | 666 | 6 to 60 months | M/F | 45 | 6 |
| Santos, 2010 | Case-control | Southeast | 132 | 2 and 6 months | M/F | 20,4 | 5 |
| Oliveira, 2010 | Cross-sectional | Southeast | 270 | 4 to 29 months | M/F | 37 | 6 |
| Righ, 2010 | Cross-sectional | Southeast | 259 | 6 to 24 months | M/F | 49,4 | 5 |
| Ferreira, 2009 | Cross-sectional | Southeast | 43 | 12 to 72 months | M/F | 7,0 | 4 |
| Reis, 2010 | Cross-sectional | Southeast | 121 | 3 to 12 months | M/F | 32,2 | 6 |
| Bortolini, 2010 | Cohort | South | 299 | 36 to 48 months | M/F | 38,1 | 7 |
| Bracco, 2011 | Non-randomized clinical trial | Northeast | 137 | 12 to 83 months | M/F | 25,5 | Serious RoB |
| Ferreira, 2011 | Cross-sectional | Northeast | 973 | 6 to 59 months | M/F | 25,6 | 6 |
| Leal, 2011 | Cross-sectional | Northeast | 1403 | 6 to 59 months | M/F | 32,8 | 6 |
| Santos, 2011 | Cross-sectional | Northeast | 595 | 6 to 59 months | M/F | 56,6 | 6 |
| Castro, 2011 | Cross-sectional | North | 617 | 6 to 60 months | M/F | 29,2 | 7 |
| Garcia, 2011 | Cross-sectional | North | 164 | 6 to 24 months | M/F | 40,5 | 6 |
| Oliveira, 2011 | Cross-sectional | North | 254 | 6 to 59 months | M/F | 57,3 | 7 |
| Souza, 2011 | Cross-sectional | North | 53 | 36 to 48 months | M/F | 58,5 | 4 |
| Azeredo, 2011 | Cross-sectional | Southeast | 327 | 6 to 18 months | M/F | 30,6 | 6 |
| Pessoa, 2011 | Cross-sectional | Southeast | 556 | 6 to 24 months | M/F | 37,9 | 7 |
| Capanema, 2011 | Cross-sectional | Southeast | 322 | 6 to 72 months | M/F | 37,3 | 5 |
| Costa, 2011 | Non-randomized clinical trial | Southeast | 667 | 50 to 82 months | M/F | 25,6 | Moderate RoB |
| Cotta, 2011 | Cross-sectional | Southeast | 446 | 6 to 84 months | M/F | 22,6 | 7 |
| Netto, 2011 | Cross-sectional | Southeast | 104 | 12 to 20 months | M/F | 26 | 6 |
| Pan, 2011 | Cross-sectional | South | 60 | 6 months | M/F | 58,3 | 6 |
| Rodrigues, 2011 | Cross-sectional | South | 256 | 6 to 24 months | M/F | 29,7 | 7 |
| Scherer, 2011 | Cross-sectional | South | 27 | 6 to 60 months | M/F | 34,7 | 5 |
| Silva, 2011 | Cross-sectional | South | 41 | 2 to 50 months | M/F | 58,5 | 4 |
| Mendes, 2012 | Cross-sectional | Midwest | 208 | zero to 72 months | M/F | 5,8 | 5 |
| Pereira, 2012 | Cross-sectional | Northeast | 99 | 6 to 59 months | M/F | 57,6 | 6 |
| Gondim, 2012 | Cross-sectional | Northeast | 1108 | 6 to 59 months | M/F | 36,5 | 7 |
| Bracco, 2011 | Non-randomized clinical trial | North | 99 | 13 to 83 months | M/F | 47,5 | Serious RoB |
| Souza, 2012 | Cross-sectional | North | 610 | 6 to 59 months | M/F | 51,8 | 7 |
| Cardoso, 2012 | Cross-sectional | North | 1111 | 6 to 10 months | M/F | 13,6 | 7 |
| Mendes, 2012 | Cross-sectional | Southeast | 126 | 6 to 72 months | M/F | 9,5 | 5 |
| Netto, 2012 | Cross-sectional | Southeast | 101 | 18 to 24 months | M/F | 30,7 | 5 |
| Rocha, 2012 | Cross-sectional | Southeast | 312 | 7 to 59 months | M/F | 30,8 | 7 |
| Hintz, 2012 | Cross-sectional | South | 590 | 6 to 72 months | M/F | 30,0 | 5 |
| Bortolini, 2012 | Randomized clinical trial | South | 369 | 12 to 16 months | M/F | 63,9 | Some concerns |
| Leite, 2013 | Cross-sectional | Midwest | 1141 | 6 to 59 months | M/F | 51,5 | 7 |
| Pedraza, 2013 | Cross-sectional | Northeast | 240 | 12 to 72 months | M/F | 15,4 | 7 |
| Leite, 2013 | Cross-sectional | Northeast | 724 | 13 to 59 months | M/F | 48,0 | 6 |
| Leite, 2013 | Cross-sectional | Northeast | 1211 | 6 to 59 months | M/F | 41,1 | 7 |
| Granado, 2013 | Cross-sectional | North | 224 | 6 to 24 months | M/F | 39,7 | 7 |
| Leite, 2013 | Cross-sectional | North | 2280 | 6 to 59 months | M/F | 66,4 | 7 |
| Castro, 2013 | Cross-sectional | Southeast | 363 | 24 to 72 months | M/F | 2,5 | 6 |
| Coutinho, 2013 | Randomized clinical trial | Southeast | 99 | 24 to 59 months | M/F | 20,2 | Low RoB |
| Nogueira-de-Almeida, 2013 | Cross-sectional | Southeast | 153 | 12 to 72 months | M/F | 25,5 | 6 |
| Oliveira, 2013 | Cross-sectional | Southeast | 980 | 12 to 72 months | M/F | 37,0 | 6 |
| Pereira, 2013 | Cohort | Southeast | 38 | 24 to 48 months | M/F | 10,5 | 4 |
| Correa, 2013 | Cross-sectional | Southeast | 374 | zero to 36 months | M/F | 10,9 | 5 |
| Dias, 2013 | Non-randomized clinical trial | Southeast | 35 | 24 to 48 months | M/F | 29,0 | Serious RoB |
| Pacheco, 2013 | Cross-sectional | South | 113 | 5 to 24 months | M/F | 11,5 | 6 |
| Silla, 2013 | Cross-sectional | South | 2376 | 18 to 72 months | M/F | 45,4 | 6 |
| Cavalcanti, 2014 | Cross-sectional | Northeast | 40 | zero to 60 months | M/F | 67,6 | 6 |
| Lander, 2014 | Cross-sectional | Northeast | 359 | 36 to 72 months | M/F | 3,9 | 7 |
| Paula, 2014 | Cross-sectional | Northeast | 945 | 6 to 59 months | M/F | 35 | 7 |
| Vasconcelos, 2014 | Cross-sectional | Northeast | 993 | 24 to 59 months | M/F | 20,9 | 7 |
| Vasconcelos, 2014 | Cross-sectional | Northeast | 777 | 6 to 23 months | M/F | 55,6 | 7 |
| Marques, 2014 | Cohort | North | 102 | 1 to 6 months | M/F | 15,7 | 5 |
| Barreto, 2014 | Cross-sectional | Southeast | 115 | 6 to 59 months | M/F | 65,2 | 5 |
| Oliveira, 2014 | Cross-sectional | Southeast | 373 | 6 to 72 months | M/F | 38,3 | 6 |
| Saraiva, 2014 | Cross-sectional | Southeast | 692 | 12 to 60 months | M/F | 15,7 | 7 |
| Stulbach, 2014 | Non-randomized clinical trial | Southeast | 136 | 6 to 24 months | M/F | 39,0 | Moderate RoB |
| Hermes, 2014 | Cross-sectional | South | 36 | 14 to 38 months | M/F | 8,3 | 5 |
| Matos, 2015 | Randomized clinical trial | Northeast | 78 | 6 to 18 months | M/F | 55,1 | Some concerns |
| Duarte, 2015 | Cross-sectional | Northeast | 92 | zero to 60 months | M/F | 23,9 | 3 |
| Ferreira, 2015 | Cross-sectional | Northeast | 55 | zero to 60 months | M/F | 20,0 | 6 |
| Lisboa, 2015 | Cross-sectional | Southeast | 725 | zero to 60 months | M/F | 37,4 | 7 |
| Silva, 2015 | Cross-sectional | Southeast | 93 | 6 to 12 months | M/F | 29 | 5 |
| Vaz-Tostes, 2015 | Non-randomized clinical trial | Southeast | 54 | 24 to 72 months | M/F | 25,0 | Serious RoB |
| Clarke, 2015 | Cross-sectional | Southeast | 409 | 6 to 71 months | M/F | 9,8 | 7 |
| Brunken, 2016 | Cross-sectional | Midwest | 100 | zero to 60 months | M/F | 23,0 | 5 |
| Pedraza, 2016 | Cross-sectional | Northeast | 299 | 9 to 24 months | M/F | 17,0 | 6 |
| Landim, 2016 | Randomized clinical trial | Northeast | 262 | 24 to 60 months | M/F | 18,3 | Some concerns |
| Arruda, 2016 | Cohort | North | 96 | 6 to 59 months | M/F | 25,3 | 6 |
| Oliveira, 2016 | Cross-sectional | North | 150 | 11 to 14 months | M/F | 23,0 | 7 |
| Oliveira, 2016 | Non-randomized clinical trial | North | 112 | 6 to 8 months | M/F | 15,2 | Moderate RoB |
| Fonseca, 2016 | Cross-sectional | Southeast | 182 | 4 to 72 months | M/F | 25,0 | 6 |
| Freitas, 2016 | Cohort | Southeast | 58 | 6 months | M/F | 31,0 | 7 |
| Zuffo, 2016 | Cross-sectional | South | 334 | 6 to 36 months | M/F | 34,7 | 7 |
| Ferreira, 2017 | Cross-sectional | Midwest | 143 | 6 to 59 months | M/F | 60,8 | 7 |
| Novaes, 2017 | Cross-sectional | Northeast | 677 | 12 to 60 months | M/F | 10,2 | 7 |
| André, 2017 | Cross-sectional | Southeast | 357 | 48 to 84 months | M/F | 9,5 | 7 |
| Lucia, 2017 | Cross-sectional | Southeast | 98 | 24 to 72 months | M/F | 11,2 | 5 |
| Mendes, 2017 | Cross-sectional | Southeast | 93 | 12 months | M/F | 25,8 | 6 |
| Nobre, 2017 | Cross-sectional | Southeast | 228 | 60 months | M/F | 15,9 | 7 |
| Man, 2017 | Cross-sectional | Southeast | 167 | 6 to 48 months | M/F | 9,6 | 6 |
| Cembranel, 2017 | Cross-sectional | South | 123 | zero to 24 months | M/F | 55,0 | 6 |
| Fischer, 2017 | Cross-sectional | South | 55 | 36 to 59 months | M/F | 1,8 | 5 |
| Rodrigues, 2017 | Randomized clinical trial | South | 533 | 12 to 15 months | M/F | 55,7 | Some concerns |
| Vieira, 2018 | Cross-sectional | Northeast | 782 | 6 to 60 months | M/F | 27,4 | 7 |
| Magalhães, 2018 | Cross-sectional | Northeast | 366 | 5 to 23 months | M/F | 26,8 | 7 |
| Melere, 2018 | Cross-sectional | South | 31 | zero and 23 months | M/F | 38,7 | 4 |
| Siqueira, 2019 | Cross-sectional | Southeast | 66 | 36 to 72 months | M/F | 27,3 | 4 |
| Silva, 2019 | Cross-sectional | Southeast | 165 | 6 to 72 months | M/F | 23,6 | 6 |
| Rocha, 2020 | Cross-sectional | Southeast | 363 | 24 to 48 months | M/F | 19,3 | 7 |

a M: male, F: female

b Newcastle-Ottawa scale for observational studies; ROBINS-I tool for non-randomized clinical trials; RoB 2 tool for randomized clinical trials.